Aravive, Inc.
DelistedCIK 1513818fmd_1B3WE12AM2VEA8SDFER7YAGGZEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2023, 44 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 40 | 1 | 5 | 6 | 7 | 9 |
| Research and development | 15 | 33 | 60 | 72 | 95 | 11 | 13 | 18 | 38 | 67 |
| Total operating expenses | 19 | 46 | 83 | 96 | 124 | 77 | 27 | 36 | 48 | 80 |
| Operating income | (19) | (46) | (83) | (96) | (84) | (75) | (22) | (31) | (41) | (71) |
| Interest expense | 0 | – | – | – | 1 | 2 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Other non-operating income (expense) | 1 | (12) | 0 | 0 | (1) | 1 | 3 | (0) | 1 | (5) |
| Income before taxes | (18) | (58) | (82) | (96) | (85) | (76) | (18) | – | – | – |
| Income tax expense | – | – | – | 0 | (0) | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | (96) | (85) | – | – | – | – | – |
| Net income | (18) | (58) | (82) | (96) | (85) | (76) | (18) | (31) | (39) | (76) |
| Net income to common shareholders | (18) | (83) | (82) | (96) | (85) | – | – | – | – | – |